ESPE Abstracts (2018) 89 FC14.1

aDevelopmental Endocrinology Research Group, School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK; bOffice for Rare Conditions, Royal Hospital for Children and Queen Elizabeth University Hospital, Glasgow, UK; cDepartment of Paediatric Endocrinology, Ghent University, Ghent, Belgium; dDepartment of Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK; eDutch Adrenal Society, t’Harde, Netherlands; fNational Centre for Rare Diseases, Istituto Superiore di Sanità, Rome, Italy; gMed. Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany; hDiabetes Center AUF DER BULT, Hannover, Germany; iUCL GOS Institute of Child Health, 30 Guilford Street, London, UK; jDepartments of Internal Medicine and Clinical Epidemiology, Leiden University Medical Centre, Leiden, Netherlands; kAPHP, Bicêtre Paris Sud, le Kremlin Bicêtre, Paris, France; lAPHP, Hôpitaux Universitaires Paris Est (AP-HP) Hôpital des Enfants Armand Trousseau, Paris, France; mPediatric Endocrinology, Karolinska University Hospital, S-17176, Stockholm, Sweden; nEndocrine Genetic Laboratory, Semmelweis University, Budapest, Hungary; oDivision of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, Milan, Italy; pDepartment of Clinical Sciences and Community Health, University of Milan, Milan, Italy; qMotol University Hospital, Prague, Czech Republic; rAcademic Centre for Thyroid Diseases, Erasmus Medical Centre, Rotterdam, Netherlands; sDivision of Paediatric Endocrinology and Diabetes, Department of Paediatrics and Adolescent Medicine, University of Lübeck, Lübeck, Germany; tDepartment of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, Netherlands

Background: Registries are of key importance for a centre of expertise. Endo-ERN consists of 71 reference centres (RCs) that cover several groups of rare endocrine conditions within 8 themes ( It is unclear if awareness, participation and availability of registries is uniform for all conditions within Endo-ERN.

Objective: To determine the extent of engagement in registries of Endo-ERN members.

Methods: Endo-ERN RC leads were invited to participate in a survey of their awareness and participation in local, national and international registries and their views on future priorities using a Likert scale of 1–5 where 5 was the greatest priority.

Results: A RC response rate of 82% was obtained. Of the 29 centres surveyed within the glucose theme, 62% reported anawareness of an international registry for rare diabetes with a 48% participation rate. A priority score of 5 was only attributed to rare diabetes. Of the 33 centres within the adrenal theme, awareness of an international registry was 61% for adrenocortical tumours (ACT) and participation was 39%. Pheochromocytoma, ACT and CAH were rated as 5. Of the 37 centres within the sex development theme, 50% reported awareness and participation was 37% for DSD; all conditions were rated as 5. Of the 43 centres within the pituitary theme, international registry awareness was 33% for pituitary adenoma whilst participation was 23%. Pituitary adenoma was the only condition rated as 5. Of the 31 centres within the rare genetic tumour theme, 19% reported an international registry awareness for MEN1 and 6% reported participation; all conditions were rated as 5. Of the 30 centres within the growth theme, international registry awareness was 17% for Prader Willi Syndrome and participation was 10%. All conditions were rated as 5. Ofthe 29 centres within the Calcium/Phosphate theme, international registry awareness was 14% for phosphate disorders and participation was 7%. Hypocalcaemia and hypophosphataemia were rated as 5. Of the 35 centres within the thyroid theme, international registry awarenessfor thyroid carcinoma was 14% and participation was 0%,with 4 of 6 conditions being rated as 5.

Conclusion: Whilst there is a clear need to develop new detailed disease registries, there is also a need to improve the awareness and signposting of existing registries. A common platform that is used by the whole endocrine community and which directs the user to high quality detailed disease registries has the potential to achieve this objective.

Article tools

My recent searches

No recent searches.